Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

NOVN

Novan (NOVN)

Novan Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:NOVN
DateTimeSourceHeadlineSymbolCompany
02/05/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NOVNNovan Inc
02/05/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NOVNNovan Inc
02/05/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NOVNNovan Inc
02/05/202401:49Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
02/05/202401:48Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
02/05/202401:44Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
02/05/202401:41Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
02/05/202401:37Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
25/03/202423:54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
27/02/202408:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
31/01/202408:47Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
27/01/202408:38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
06/01/202401:23GlobeNewswire Inc.Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in IndianapolisNASDAQ:NOVNNovan Inc
22/12/202308:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
11/12/202311:30GlobeNewswire Inc.Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)NASDAQ:NOVNNovan Inc
09/12/202301:15GlobeNewswire Inc.Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissionsNASDAQ:NOVNNovan Inc
06/12/202311:16GlobeNewswire Inc.Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHNASDAQ:NOVNNovan Inc
20/11/202317:15GlobeNewswire Inc.Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASHNASDAQ:NOVNNovan Inc
25/10/202308:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
21/10/202308:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
08/09/202306:58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
25/08/202306:31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
27/07/202306:50Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
18/07/202306:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
17/07/202323:23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
17/07/202322:45GlobeNewswire Inc.Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 ProtectionNASDAQ:NOVNNovan Inc
07/07/202307:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
28/06/202308:30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NOVNNovan Inc
17/06/202307:02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NOVNNovan Inc
12/06/202323:06Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NOVNNovan Inc
 Showing the most relevant articles for your search:NASDAQ:NOVN

Your Recent History

Delayed Upgrade Clock